Linked Life Data

9056144

Source:http://linkedlifedata.com/resource/pubmed/id/9056144

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1997-5-12
pubmed:abstractText
Technetium-99m-sestamibi scintigraphy has recently emerged as a new procedure for the imaging of malignant breast tumors. A large clinical experience has now been collected and this article reviews the main published results. The major drawback of the procedure appears to be its low sensitivity in detecting lesions smaller than 1 cm. The biological background underlying the tracer accumulation is also described. The stimulating potent applications of this functional imaging technique to non-invasively explore the development, and possibly the reversal, of a multidrug resistance under chemotherapy are discussed. The data related to the use of the positron emitter fluor-18-labeled fluorodeoxyglucose (FDG), a very promising agent for imaging breast as well as other solid tumors, are also reviewed. This situation of specific agents, still under development and such as labeled receptor ligands, is examined.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0720-048X
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2-10
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Scintigraphic imaging of breast tumors.
pubmed:affiliation
Division of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France. jean.maublant@cjp.u-clennontl.fr
pubmed:publicationType
Journal Article, Review